PTC/SB/08a (08-03)
Approved for use through 97/31/2006, ONE 0651-0201
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	
	Filing Date	
	First Named Inventor Ymi	n Chen
(Not for submission under 37 CFR 1.99)	Art Unit	
(Notice Submission and of the first)	Examiner Name	
	Attorney Docket Number	CYN-114US

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wisl	If you wish to add additional U.S. Patent citation information please click the Add button. Add										
	U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	Name of Patentee or Applic of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³			e or	Pages,Colun where Relev Passages or Figures App	ant Relevant	T5			
	1	CN2471154Y	CN			2002-01-16	Yımin Chen				
	2	CN2507281Y	CN			2002-08-28	Hai Ren				
	3	CN2595208Y	CN			2003-12-31	Ymin Chen				

Application Number Fing Date STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99) Remainder 1991 Application Number Find Date First Number Invariance Inva

1993.06.09 Doamo D A

Date Considered

	5	DE3417497A1	DE		1985-11-14	Laabs W A			
	6	CN2429009Y	CN		2001-05-09	Yımin Chen			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner (initials* Cite (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5		
	1								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
FYAMINER SIGNATURE									

1 See Kinz Codes of USPTO Potent Documents at twent_USET_LOCU/or MEPE 981.64. 2 Enter often that issued the document, by the two-lets of (MPD Standard 513.) 2 "For Jumpines patient outcomests, the collection of the year of the register that precise the certain protect the seal manufacture. 4 "Kind of document by the appropriate symbols as addicated on the document under WIPO Standard 51.16 if possible. 2 Applicant is to place a check mark here if English targinguise thresistors is addicated.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

CD2262024A

Application Number Filing Date Filing Date Filing Date First Number Inventor | Yenin Chen Art Unit Examiner Name | Examiner Na

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sideosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Tianhua Gu/	Date (YYYY-MM-DD)	2006-09-02
Name/Print	Tianhua Gu	Registration Number	52480

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, V.S. Organized to Complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, V.S. Organized to Comment of Comment

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.